Indivior Pharmaceuticals Inc

Indivior Reports Third Quarter 2026 Financial Results

Indivior reported record Q3 2026 results with total net revenue of $356 million, up 13% year-over-year, and record SUBLOCADE net revenue of $267 million, up 22%. Profitability inflected sharply: GAAP net income hit a record $137 million ($1.12 diluted EPS), non-GAAP net income $161 million ($1.32), and Adjusted EBITDA rose 76% YoY to $211 million on a 59% margin, up 2,100 basis points. The company reaffirmed its standalone FY2026 guidance (net revenue $1,295M-$1,365M, Adjusted EBITDA $700M-$740M) and confirmed the all-stock merger of equals with Supernus is on track to close November 2, 2026. Upon closing, the combined company will trade as Supernus, Inc. under ticker SUPN beginning November 3, meaning INDV shareholders will hold Supernus stock, with a special cash dividend contingent on the deal closing.

•3d ago

Updated Effective Date: Huron Consulting Group Set to Join S&P SmallCap 600

Huron Consulting Group will join the S&P SmallCap 600 before the open on Tuesday, November 3, one day later than the originally announced November 2 effective date. S&P DJI revised the date due to a special dividend ex-date announcement tied to Indivior Pharmaceuticals' pending acquisition of Supernus Pharmaceuticals, which frees HURN's index slot. Index inclusion typically triggers passive-fund buying of HURN shares ahead of the effective date.

•4d ago

Indivior Pharmaceuticals, Inc. Declares Special Cash Dividend

Indivior's board declared a special cash dividend of $8.13 per share, payable to holders of record as of October 30, 2026, with holders of equity awards entitled to $8.13 per underlying share upon vesting. Payment is contingent on the closing of the previously announced merger with Supernus Pharmaceuticals, expected on or about November 2, 2026 — if the merger fails for any reason, no dividend will be paid. Assuming an on-time close, payment is anticipated on or about November 6, 2026. Supernus stockholders will not receive the dividend on Indivior shares obtained as merger consideration, and the release's risk factors disclose the dividend will be funded with additional indebtedness, adding leverage to the combined company.

•1mo ago

Indivior Reports Second Quarter 2026 Financial Results and Raises Full-Year 2026 Guidance

Indivior reported Q2 revenue of $343 million, up 14% year-over-year, driven by a 21% increase in SUBLOCADE sales to a record $253 million. Adjusted EBITDA surged 111% to a record $186 million, prompting the company to raise its full-year revenue guidance to $1.295-$1.365 billion and EBITDA guidance to $700-$740 million. The company repurchased approximately 4.7 million shares for $175 million during the quarter and announced a definitive agreement to merge with Supernus Pharmaceuticals in an all-stock transaction.

•2mo ago

Supernus Pharmaceuticals and Indivior Pharmaceuticals to Merge, Creating a Diversified CNS Biopharmaceutical Leader with Significant Scale

Indivior Pharmaceuticals and Supernus Pharmaceuticals agreed to a definitive all-stock merger of equals, creating a CNS biopharmaceutical leader with $2.2 billion in combined annual revenue and expected synergies of $125 million. Indivior shareholders will receive a one-time special cash dividend of $1.0 billion and own approximately 56.5% of the combined company, which will be named Supernus, Inc. and trade under the ticker SUPN. The transaction is expected to close in Q4 2026, with Jack Khattar serving as CEO and the company securing a $650 million term loan to help fund the dividend.

•2mo ago

New Studies Show Adherence to Monthly Injectable Buprenorphine is Associated with Relapse Reduction and Lower Healthcare Utilization

Indivior announced findings from two new real-world evidence studies showing that adherence to its monthly injectable buprenorphine, SUBLOCADE, is associated with significantly lower relapse risk and reduced healthcare utilization. The first study, analyzing 3,400 patients, found that those adherent to extended-release buprenorphine were 3.5 to 8.1 times less likely to return to opioid use compared to non-adherent patients or those on other forms of medication-assisted treatment. A second study comparing 467 patients on monthly injectable buprenorphine to nearly 120,000 on daily oral buprenorphine showed a 62% reduction in bacteremia incidence, along with 56% fewer inpatient visits and 22% fewer emergency department visits.

•5mo ago

Indivior Announces $175 Million Accelerated Share Repurchase

Indivior entered into a $175 million accelerated share repurchase agreement with Barclays Bank PLC under its existing $400 million authorization. The company paid upfront and received an initial delivery of 3,717,473 shares, with final settlement expected by the end of June based on volume-weighted average price. The remaining $100 million authorization is available for future repurchases, and the ASR is not expected to impact previously issued financial guidance.

•5mo ago